<DOC>
	<DOCNO>NCT00088556</DOCNO>
	<brief_summary>The purpose trial study efficacy safety triplet combination TLK286 , carboplatin paclitaxel first-line therapy patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Carboplatin , Paclitaxel TLK286 ( Telcyta ) First-Line Therapy Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>18 year age old Histologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IV IIIB ( disease eligible combine modality chemotherapy radiation ) Measurable disease RECIST ECOG status 01 Adequate liver renal function Adequate bone marrow reserve Prior chemotherapy , immunotherapy biologic therapy metastatic NSCLC Up one prior adjuvant neoadjuvant chemotherapy allow History bone marrow transplantation stem cell support Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>